Hjem › Astrocytom
Astrocytom kliniske forsøg rekrutterer i USA
45 studier for Astrocytom rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Houston, TX14 studier
- Boston, MA13 studier
- Chicago, IL9 studier
- New York City, NY9 studier
- Miami, FL7 studier
- Philadelphia, PA7 studier
- Columbus, OH6 studier
- Seattle, WA6 studier
- Washington, DC6 studier
- Durham, NC6 studier
- San Francisco, CA6 studier
- Cincinnati, OH5 studier
- Aurora, CO5 studier
- Salt Lake City, UT5 studier
- Baldwin Park, CA4 studier
- St. Louis, MO4 studier
- Birmingham, AL3 studier
- Ann Arbor, MI3 studier
- Lexington, KY3 studier
- San Antonio, TX3 studier
- Los Angeles, CA3 studier
- Edison, NJ3 studier
- Dallas, TX3 studier
- Kansas City, KS3 studier
- New Haven, CT3 studier
- Pittsburgh, PA3 studier
- Detroit, MI3 studier
- Nashville, TN3 studier
- Rochester, MN3 studier
- Queens, NY3 studier
Efter delstat
- Alabama3 studier
- Californien10 studier
- Colorado5 studier
- Connecticut3 studier
- District of Columbia4 studier
- Florida9 studier
- Georgia3 studier
- Illinois9 studier
- Kansas3 studier
- Kentucky4 studier
- Massachusetts13 studier
- Michigan6 studier
- Minnesota5 studier
- Missouri4 studier
- New Jersey3 studier
- New York9 studier
- North Carolina7 studier
- Ohio8 studier
- Pennsylvania8 studier
- Tennessee4 studier
- Texas15 studier
- Utah5 studier
- Virginia3 studier
- Washington7 studier
- Wisconsin3 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RekruttererFase 3
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07215910GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07301268MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT03896568Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06047379A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT05765812VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
RekruttererFase 2
Alder 18 til 98 · Alle køn · Opdateret 21. sep. 2026 · NCT07831369A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
RekruttererFase 1
Alder 19 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT05698524SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
RekruttererFase 1/2
Alder 2 til 24 · Alle køn · Opdateret 11. sep. 2026 · NCT04923126FearLess in NeuroOncology
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06989086Targeted Pediatric High-Grade Glioma Therapy
RekruttererObservationsstudie
12 Months – 39 Years · Alle køn · Opdateret 8. sep. 2026 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RekruttererFase 1
36 Months – 22 Years · Alle køn · Opdateret 4. sep. 2026 · NCT03911388Serial MRI Scans During Radiation Therapy
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT04188535Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
RekruttererFase 2
Alder 12 til 39 · Alle køn · Opdateret 1. sep. 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT05303519Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
RekruttererFase 1
Alder 18 til 120 · Alle køn · Opdateret 14. aug. 2026 · NCT06344130Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RekruttererFase 1/2
Alder 18 til 130 · Alle køn · Opdateret 12. aug. 2026 · NCT05417594Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT07544992Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 7. aug. 2026 · NCT07733674Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 16. jul. 2026 · NCT04623931Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 29. jun. 2026 · NCT06815029Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RekruttererTidlig fase 1Frivillige med god helbredstilstand velkomne
Alder 1 til 21 · Alle køn · Opdateret 29. jun. 2026 · NCT06333899Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 24. jun. 2026 · NCT07468136A Study of 177Lu-PSMA-617 in People With Gliomas
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 4. jun. 2026 · NCT07223034Loupe-Based Intraoperative Fluorescence Imaging
RekruttererObservationsstudie
Alder 18 til 90 · Alle køn · Opdateret 3. jun. 2026 · NCT04780009Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.